title: Patterns of ovarian response to gonadotropin stimulation in female carriers of balanced translocation.
abstract: OBJECTIVE
  To determine whether maternal balanced translocation is a risk factor for poor ovarian response to controlled ovarian hyperstimulation (COH).
  
  
  METHODS
  A retrospective analysis.
  
  
  METHODS
  Private IVF center.
  
  
  METHODS
  All couples presenting to a single center for preimplantation genetic diagnosis (PGD) for autosomal balanced translocation in either partner from 1995 through 2001.
  
  
  METHODS
  Cycle parameters and embryology outcomes were examined and compared between two groups: 61 cycles in 46 women with balanced translocations compared with 42 cycles in 32 women whose male partner had a balanced translocation.
  
  
  METHODS
  Response to ovarian stimulation.
  
  
  RESULTS
  In couples undergoing IVF/PGD to avoid transmission of an unbalanced karyotype, a significantly higher proportion of women carrying balanced translocations (female carrier) responded very poorly (E2 on the day of hCG <1,000 pg/mL) to ovarian stimulation compared to women whose partner had a balanced translocation (male carrier) (23.0% vs. 7.1%).
  
  
  CONCLUSIONS
  In couples undergoing IVF/PGD for balanced translocation, the risk for poor response to ovarian stimulation may be increased when the female partner carries the balanced translocation compared to when the male partner carries the translocation. Given significant embryo attrition due to chromosomal imbalance, aggressive stimulation should be considered if the patient does not have risk factors for ovarian hyperstimulation syndrome (OHSS).
authors.affiliation: Institute for Reproductive Medicine and Science (IRMS), Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, Saint Barnabas Medical Center, Livingston, New Jersey 07039, USA. serenac@sbivf.com
authors.forename: Serena H
authors.initials: SH
authors.lastname: Chen
authors.forename: Tomas
authors.initials: T
authors.lastname: Escudero
authors.forename: Natalie A
authors.initials: NA
authors.lastname: Cekleniak
authors.forename: David B
authors.initials: DB
authors.lastname: Sable
authors.forename: Margaret G
authors.initials: MG
authors.lastname: Garrisi
authors.forename: Santiago
authors.initials: S
authors.lastname: Munne
mesh_terms: D000328:Adult; D016009:Chi-Square Distribution; D006063:Chorionic Gonadotropin / Q000494:pharmacology*; D016001:Confidence Intervals; D005260:Female; D006579:Heterozygote; D006801:Humans; D008297:Male; D010062:Ovulation Induction / Q000706:statistics & numerical data*; D019836:Preimplantation Diagnosis / Q000706:statistics & numerical data; D012189:Retrospective Studies; D012307:Risk Factors; D014178:Translocation, Genetic / Q000187:drug effects / Q000235:genetics*
chemical_list: D006063:Chorionic Gonadotropin